Study of SHR-1819 injection for teens with severe eczema
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 17 years old and weigh at least 30 kg (66 lbs).
- You must have had eczema (atopic dermatitis) for at least 6 months, and it must be severe (covering at least 10% of your body, with high scores on skin and itch scales).
- Your itching must be rated at least 4 out of 10 on average over the past week.
- You must have tried prescription creams or other treatments for eczema without good results, or those treatments are not safe for you.
- You must agree to use a plain moisturizer twice daily for at least 7 days before starting the study.
- You and your parent or guardian must sign a consent form and follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, MG-K10, given as an injection, to see if it can reduce eczema symptoms like itching and skin rash in teenagers. It's for teens whose eczema is not well controlled with topical treatments.
This trial tests a new drug called SHR-1905 for people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and helps improve symptoms.
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
This study tests a new medicine (called 611) given as an injection to children with moderate-to-severe eczema that hasn't improved with creams. The goal is to see if it can reduce itching and clear the rash.
This study tests an injection called ADSTEM for people with moderate to severe eczema (atopic dermatitis) that hasn't improved with standard creams or other treatments. The goal is to see if it can help reduce symptoms like itching and rash.
This trial tests an investigational drug called SM17 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if SM17 can reduce itching and skin symptoms when topical treatments haven't worked well enough.
Hear when a new Adolescents With Moderate-to-severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.